SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Add                               | litess of Reportin | a Person*                                    | 2. Date of Even                                 |                   | 3. Issuer Name and Ticker or Trad  | ding Symbol                        |   |  |   |
|---|--------------------|--|---|-------------------|--|------------------------------------|---|--|---|
| <u>NeoMed In</u>                              |                    |  | Requiring State<br>(Month/Day/Yea<br>11/15/2017 | ment              | <u>Arsanis, Inc.</u> [ ASNS ]  |                                    |   |  |   |
| (Last) (First) (Middle)<br>13 CASTLE STREET   |                    |  |   |                   | 4. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>Director X 10% Owner<br>Officer (give title Other (specify |                                    |   | <ul> <li>5. If Amendment, Date of Original Filed<br/>(Month/Day/Year)</li> <li>6. Individual or Joint/Group Filing (Check</li> </ul> |   |
| (Street)<br>ST HELIER Y9 JE4 5UT              |                    |  |   |                   | below) below)  |                                    |   | Applicable Line)<br>Form filed by One Reporting Person<br>X Form filed by More than One<br>Reporting Person                          |   |
| (City)  | (State)            | (Zip)  |   |                   |  |                                    |   |  |   |
|   |                    |  | Table I - No                                    | n-Deriva          | tive Securities Beneficial   | ly Owned                           |   |  |   |
| 1. Title of Security (Instr. 4)               |                    |  |   |                   | 2. Amount of Securities<br>Beneficially Owned (Instr. 4)<br>or Indirect (I)<br>(Instr. 5)<br>4. Nature of Indirect Benefic<br>(Instr. 5) |                                    | t Beneficial Ownership                      |  |   |
|   |                    | (6   |   |                   | e Securities Beneficially ants, options, convertible   |                                    | s)  |  |   |
| 1. Title of Derivative Security (Instr. 4) 2. |                    |  | 2. Date Exer<br>Expiration D<br>(Month/Day/     | cisable an<br>ate |  | ties                               | 4.<br>Conversio                             | e Form:  | 6. Nature of Indirect<br>Beneficial Ownership<br>(Instr. 5) |
|   |                    | Date<br>Exercisable                          | Expiratio<br>Date                               | n<br>Title        | Amount<br>or<br>Number<br>of<br>Shares   | Price of<br>Derivative<br>Security | Direct (D)<br>or Indirect<br>(I) (Instr. 5) |  |   |
| Series B Conv                                 | ertible Preferr    | ed Stock                                     | (1)   | (1)               | Common Stock   | 246,682                            | (1)   | D <sup>(4)</sup>   |   |
| Series C Conv                                 | ertible Preferr    | ed Stock                                     | (2)   | (2)               | Common Stock   | 41,878                             | (2)   | <b>D</b> <sup>(4)</sup>  |   |
| Series D Conv                                 | ertible Preferr    | ed Stock                                     | (3)   | (3)               | Common Stock   | 279,079                            | (3)   | D <sup>(4)</sup>   |   |
| NeoMed In<br>(Last)<br>13 CASTLE S            | (First)            | <u>L.P.</u><br>(Middl                        | e)  | -                 |  |                                    |   |  |   |
| (Street)<br>ST HELIER Y9 JE4 5UT              |                    |  | JUT   | _                 |  |                                    |   |  |   |
| (City)  | (State)            | (Zip)  |   |                   |  |                                    |   |  |   |
| 1. Name and Add<br><u>NeoMed M</u>            |                    | g Person <sup>*</sup><br><u>(Jersey) Ltd</u> |   |                   |  |                                    |   |  |   |
| (Last)<br>13 CASTLE S                         | (First)<br>STREET  | (Middl                                       | e)  | -                 |  |                                    |   |  |   |
| (Street)<br>ST HELIER Y9 JE4 5U               |                    |  | JUT   | _                 |  |                                    |   |  |   |
| (City)  | (State)            | (Zip)  |   |                   |  |                                    |   |  |   |
| 1. Name and Add<br><u>NeoMed In</u>           |                    |  |   |                   |  |                                    |   |  |   |
| (Last)<br>13 CASTLE S                         | (First)            | (Middl                                       | e)  |                   |  |                                    |   |  |   |
| (Street)<br>ST HELIER                         | ¥9                 | JE4 5  | JUT   | -                 |  |                                    |   |  |   |

| (City) | (State) | (Zip) |  |
|--------|---------|-------|--|
|--------|---------|-------|--|

### Explanation of Responses:

1. The Series B Convertible Preferred Stock is convertible into Common Stock on a 0.44650-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

2. The Series C Convertible Preferred Stock is convertible into Common Stock on a 0.49832-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

3. The Series D Convertible Preferred Stock is convertible into Common Stock on a 0.29300-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

4. The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P. except to the extent of its or his pecuniary interest therein, if any.

## **Remarks:**

Exhibit Index: 24.1 Power of Attorney 24.2 Power of Attorney 24.3 Power of Attorney

| /s/ Mike Gray, as attorney-in-<br>fact on behalf of NeoMed<br>Innovation V L.P.           | <u>11/15/2017</u> |
|---|-------------------|
| /s/ Mike Gray, as attorney-in-<br>fact on behalf of NeoMed<br>Management (Jersey) Limited | <u>11/15/2017</u> |
| /s/ Mike Gray, as attorney-in-<br>fact on behalf of NeoMed<br>Innovation V Limited        | <u>11/15/2017</u> |
| ** Signature of Reporting Person  | Date              |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

#### LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Rene Russo and Mike Gray, signing singly and each acting individually, as the undersigned's true and lawful attorney-in-fact with full power and authority as hereinafter described to:

(1) execute for and on behalf of the undersigned, Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the "Exchange Act");

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority, including without limitation the filing of a Form ID or any other application materials to enable the undersigned to gain or maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC;

(3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the securities of Arsanis, Inc. (the "Company") from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 31st day of October, 2017.

NEOMED INNOVATION V L.P. By: NeoMed Innovation V Limited Its: General Partner

> By: /s/ Tamara Williams Tamara Williams Its: Director

- By: /s/ Oliver Morris Oliver Morris
- Its: Alternate Director

#### LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Rene Russo and Mike Gray, signing singly and each acting individually, as the undersigned's true and lawful attorney-in-fact with full power and authority as hereinafter described to:

(1) execute for and on behalf of the undersigned, Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the "Exchange Act");

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority, including without limitation the filing of a Form ID or any other application materials to enable the undersigned to gain or maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC;

(3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the securities of Arsanis, Inc. (the "Company") from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 9th day of November, 2017.

NEOMED MANAGEMENT (JERSEY) LIMITED

By: /s/ Tamara Williams Tamara Williams

- Its: Director
- By: /s/ Oliver Morris Oliver Morris Its: Alternate Director

#### LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Rene Russo and Mike Gray, signing singly and each acting individually, as the undersigned's true and lawful attorney-in-fact with full power and authority as hereinafter described to:

(1) execute for and on behalf of the undersigned, Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the "Exchange Act");

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority, including without limitation the filing of a Form ID or any other application materials to enable the undersigned to gain or maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC;

(3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the securities of Arsanis, Inc. (the "Company") from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 9th day of November, 2017.

NEOMED INNOVATION V LIMITED

Its: Director

By: /s/ Tamara Williams Tamara Williams

By: /s/ Oliver Morris Oliver Morris Its: Alternate Director